Oncoteq, a clinical stage biotech company specializing in innovative cancer treatments, today announces its second in-licensing deal as it obtains a world-wide exclusive license to a novel compound with potential to shift the paradigm in breast cancer treatment. The first-in-class compound TEQ103 (formerly SERA2) is a selective estrogen receptor activator, which specifically targets cancer cells expressing estrogen receptor alpha and in mouse models induces complete regression of tumors that are resistant to current treatments. The deal represents Oncoteq’s second in-licensing of a potential first-in-class or best-in-class cancer treatment following its transaction with Merck KGaA in 2022. The company will continue to seek opportunities with which to expand its growing oncology-focused pipeline. 

Read more in the attached press release.